In the last conf. call they said they have roughly $10mil currently and that it is not enough to finish the trials but is enough to hold them for a while. I don't think they plan on raising more capitol at this stock price anytime soon. The trial costs would seem to increase as they get into the p3 mono trial where they need to pay for a longer term 300 patient trial. that isn't until some point in 2017. The other trials are much cheaper. My impression is that they are going to raise the capitol they need as the stock price is at a higher level. On the other hand, they have no control of the stock price and do have to pay for the trials no matter what.
Market Data 
Markets 
AI
